Two studies have underlined the extreme need for caution in patients suffering kidney disease and also undergoing treatment to reverse anemia by increasing the count of red blood cells, beyond FDA regulated levels.
One of the studies in question had to be abandoned after researchers reported impediments in the high-hemoglobin group. Further the treatment did not achieve the envisaged results.
FDA has confirmed that it would relook at the data from the study and ascertain the permissible limit of anemia rectification, without fear of an adverse reaction.
There are also aspersions being cast on specialists, if they are going overboard on ant-anemia drugs. Lead author of the study, Dr. Ajay Singh, clinical chief of the renal division and director of dialysis at Brigham and Women's Hospital in Boston, said, Treatment of anemia is important, but care needs to be taken in how aggressively anemia is treated. The current evidence suggests that too high a hemoglobin level may be associated with some risk."